ISN Journal Editorial Selections on aHUS Management, Rituximab Therapy, Methylmalonic Acidemia, and Rare Kidney Diseases
Kidney International® Outcomes From the International Society of Nephrology Hemolytic Uraemic Syndromes International Forum The 2023 ISN aHUS Forum brought together global experts to discuss key challenges in managing complement-mediated hemolytic uraemic syndromes (HUS), including nomenclature, biomarkers, and treatment protocols. Key areas for future research were identified, such as genetic predisposition, optimal complement inhibitor use, and improving...